Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I
文献类型：期刊论文
| 作者 | Yuankai Shi1; Jianying Zhou2; Yanqiu Zhao3; Bo Zhu4; Liangming Zhang5; Xingya Li3; Jian Fang6; Jianhua Shi7; Zhixiang Zhuang8; Sheng Yang1 |
| 刊名 | BMC MEDICINE
 |
| 出版日期 | 2023 |
| 卷号 | 21期号:1 |
| ISSN号 | 1741-7015 |
| 英文摘要 | Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This phase IIa study was part of a phase I EGFR mutated non-small cell lung cancer (NSCLC). |
| 语种 | 英语 |
| 源URL | [http://ir.yic.ac.cn/handle/133337/34554]  |
| 专题 | 中国科学院烟台海岸带研究所 |
| 作者单位 | 1.中国医学科学院北京协和医学院 2.浙江大学 3.郑州大学 4.Institute of Cancer, Xinqiao Hospital, Third Military Medical University 5.中国科学院烟台海岸带研究所 6.Beijing Cancer Hospital 7.Linyi Cancer Hospital 8.苏州大学 9.重庆大学 10.徐州医科大学 |
| 推荐引用方式 GB/T 7714 | Yuankai Shi,Jianying Zhou,Yanqiu Zhao,et al. Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I[J]. BMC MEDICINE,2023,21(1). |
| APA | Yuankai Shi.,Jianying Zhou.,Yanqiu Zhao.,Bo Zhu.,Liangming Zhang.,...&Tingting Wang.(2023).Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I.BMC MEDICINE,21(1). |
| MLA | Yuankai Shi,et al."Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I".BMC MEDICINE 21.1(2023). |
入库方式： OAI收割
来源：烟台海岸带研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。